Other medical trials in sufferers with non-Hodgkin's lymphoma [24] and clients with Highly developed malignancy [fourteen] have demonstrated also that zosuquidar didn't noticeably have an affect on the pharmacokinetics of doxorubicin and experienced reasonable results over the pharmacokinetics of vincristine. These medical trials authorized that zo